bullish

Sartorius AG

Sartorius AG (SRT GR): Strong 1Q25 Result; Positive Takeaway For Bioprocessing Industry

662 Views19 Apr 2025 23:07
​Sartorius sees 21% YoY increase in net profit for 1Q25 on 7% sales growth. The company expects 6% sales growth in 2025 with EBITDA margin improvement. Result is positive for biopharma CDMO players.
What is covered in the Full Insight:
  • Overview of Sartorius AG's 1Q25 Performance
  • Bioprocessing Solutions Division as a Growth Engine
  • 2025 Financial Guidance by Sartorius
  • Implications for Downstream Bioprocessing Companies
  • Future Outlook and Competitor Updates
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x